Source comparison
Comparison Table: PT-141 vs Alternative Female Sexual Dysfunction Treatments
PT-141 (Bremelanotide) MC4R agonist. Central nervous system activation Subcutaneous injection 45–90 minutes 6–12 hours Approved for premenopausal HSDD (2019) 0.3–0.5 point mean increase in FSFI desire domain Nausea (40%), flushing (20%), headache (11%) Effecti
This comparison does not assign a generated winner or score.
- PT-141 (Bremelanotide)
- MC4R agonist. Central nervous system activation
- Subcutaneous injection
- 45–90 minutes
- 6–12 hours
- Approved for premenopausal HSDD (2019)
- 0.3–0.5 point mean increase in FSFI desire domain
- Nausea (40%), flushing (20%), headache (11%)
- Effective for arousal independent of hormonal or vascular status. Nausea limits tolerability for some users
- Flibanserin (Addyi)
- Serotonin receptor modulation (5-HT1A agonist, 5-HT2A antagonist)
- Daily oral tablet
- 4–8 weeks (chronic dosing required)
- Continuous while on treatment
- Approved for premenopausal HSDD (2015)
- 0.3–0.4 point mean increase after 24 weeks
- Dizziness (11%), somnolence (11%), contraindicated with alcohol
- Requires daily adherence. Effect builds over weeks rather than on-demand
- Testosterone Therapy (Off-Label)
- Androgen receptor activation
- Transdermal cream or pellet implant
- 2–4 weeks
- Not FDA-approved for female sexual dysfunction
- Variable. Inconsistent trial results
- Acne, hirsutism, voice deepening, lipid changes
- May help in cases of documented androgen deficiency but evidence for HSDD is mixed
- Ospemifene (Osphena)
- Selective estrogen receptor modulator (SERM)
- 4–12 weeks
- Approved for dyspareunia due to vulvovaginal atrophy (2013)
- Not measured. Addresses pain, not desire
- Hot flashes, vaginal discharge, increased VTE risk
- Targets genitourinary symptoms in postmenopausal women. Does not directly affect libido
- PDE5 Inhibitors (Off-Label)
- Phosphodiesterase-5 inhibition. Increases genital blood flow
- Oral tablet
- 30–60 minutes
- 4–6 hours (sildenafil), 24–36 hours (tadalafil)
- Minimal efficacy in women without vascular impairment
- Headache, flushing, visual disturbances
- Works peripherally. Limited evidence for improving desire or arousal in women